January 22, 2008 / 2:33 PM / 11 years ago

J&J Cypher sales plunge, hurt by fewer procedures

NEW YORK, Jan 22 (Reuters) - Johnson & Johnson (JNJ.N) on Tuesday said fourth-quarter global sales of its Cypher stent plunged 31 percent to $415 million, hurt by rival products and blood-clot concerns that have prompted doctors to perform fewer stenting procedures.

J&J officials, in a conference call with industry analysts and investors, said global market share of Cypher slipped 6 percentage points in the quarter, compared with the year-ago period, to 42 percent.

U.S. sales of Cypher fell more than 32 percent to $190 million, J&J said. (Reporting by Ransdell Pierson, editing by Gerald E. McCormick)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below